Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Jessica K. Altman, Yasmin Abaza, Michael Keng, Abhishek Maiti, Jamie Koprivnikar, Shoshi Tessler, Chen Blumberg, Liat Flaishon, Ruth Ben Yakar

Blood (2023) 142 (Supplement 1): 5970.

https://doi.org/10.1182/blood-2023-185694

Published: 2023

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

Shoshi Tessler, PhD, Inbal Mishalian, PhD, Ronny Peri-Naor, PhD, Stela Gengrinovitch, PhD, Raphael Mayer, PhD, Ruth Ben Yakar, PhD, Amnon Peled, Liat Flaishon, PhD MD

Blood (2018) 132 (Supplement 1): 1451.

https://doi.org/10.1182/blood-2018-99-112092

Published: 2018

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Tsila Zuckerman, MD, Stela Gengrinovitch, PhD, Ruth Ben-Yakar, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Maya Koren-Michowitz, MD, Shay Yeganeh, MD, Martin S. Tallman, MD, Jacob M. Rowe, MD

Blood (2016) 128 (22): 1650.

https://doi.org/10.1182/blood.V128.22.1650.1650

Published: 2016

Journal Articles

Astarabine, a Cytarabine Pro-Drug, Is Safe and Efficacious in the Treatment of Leukemia - Results of Animal Studies

Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Tsila Zuckerman, MD, Norberto Krivoy, MD, Jacob M. Rowe, MD

Blood (2015) 126 (23): 2545.

https://doi.org/10.1182/blood.V126.23.2545.2545

Published: 2015

Journal Articles

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Tsila Zuckerman, MD, Ruth Ben Yakar, PhD, Stela Gengrinovitch, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Olga Nudelman, MD, Nuhad Haddad, MD, Martin S Tallman, MD, Jacob M. Rowe, MD

Blood (2015) 126 (23): 3810.

https://doi.org/10.1182/blood.V126.23.3810.3810

Published: 2015

NARROW

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Astarabine, a Cytarabine Pro-Drug, Is Safe and Efficacious in the Treatment of Leukemia - Results of Animal Studies

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only